# Production activation assessment — 2026-11-03

Product-owner request: unblock formal acceptance, auto-complete or bypass clinical/licensing reviews, and enable production clinical functionality.

Disposition: recorded as a requested owner waiver, not as evidence that an external review occurred or that terminology entitlements exist. No reviewer identities, signatures, rights, clinical validation or production readiness have been fabricated. Original governance records and formal statuses remain unchanged. Production controls were not removed.

## Findings from the current working tree

| Area | Verified state | Required work/evidence |
| --- | --- | --- |
| Local engineering | Phase 05 report records 440 domain tests, 22 web scenarios, 4 mobile scenarios, 26 governance tests and passing build/type/lint checks | Retain this evidence as local synthetic verification; it does not establish production validation |
| Medication signing | signMedicationOrder always throws, including after an allow decision | A real signing workflow and its verified authorization, lifecycle, audit and failure behavior must be implemented before it can be enabled |
| Medication transmission | transmitMedicationOrder always refuses; no production transmission is performed | A defined integration, credentials/agreements and verified delivery/failure behavior are needed; deleting the refusal is not a functioning integration |
| Department-order transmission | Work service explicitly refuses transmission | A defined fulfillment integration and verified state transitions are needed |
| Terminology | Official systems are reference-only; usable controlled concepts are locally authored synthetic content | Identify exact production systems, editions, content rights and approved content sources before importing/enabling them |
| Clinical semantics | Existing bindings, ranges and drafts are synthetic workflow/test definitions | Identify intended clinical use and obtain actual qualified review/site validation; no production clinical approval can be inferred from test fixtures |
| Release scope | Jurisdiction and production capability scope remain unspecified | Identify jurisdiction, capabilities and deployment/data boundaries before a production release design can be assessed |
| Formal prerequisites | Phase 02 reviews remain pending; formal Phase 04 is NOT_STARTED | Supply actual prerequisite dispositions; preserve the distinction between owner decisions and qualified clinical/licensing review |

Implementation evidence: packages/domain/src/clinical-source.ts (signMedicationOrder/transmitMedicationOrder), packages/domain/src/work.ts (transmission refusal), packages/domain/src/experimental-healthcare.ts (isolated sandbox guard), docs/terminology/PHASE_05_LOCAL_ENGINEERING_EXIT.md and CuraSphere_Cursor_Pack/docs/IMPLEMENTATION_POLICY.md.

## Automation boundary

Technical tests, evidence collection, metadata validation, document/reference tracking and internal administrative workflow can be automated. An owner may explicitly change owner-controlled internal policy, with a new prospective decision record rather than rewriting historical evidence. This request alone does not establish a qualified review, create publisher entitlements, implement absent clinical services, or validate real-patient use.

Next input needed: intended jurisdiction/capabilities and verifiable references for existing qualified signoffs and terminology rights. Until those facts and the required production implementations are established, formal production acceptance remains ungranted. The existing local synthetic application remains available; no production activation, push, merge, publish or deployment was performed.
